Pexidartinib

CHEMBL3813873 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
417.8 g/mol
LogP
4.5
Phase
4

A kinase inhibitor used to treat tenosynovial giant cell tumor, a rare and often debilitating condition causing benign but destructive tumors in the joint lining. It works by blocking a signaling pathway that drives the abnormal growth of these tumor cells.

分子量

417.8000 g/mol

LogP

4.50

TPSA

66.50 Ų

Lipinski 五规则

符合

治疗领域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1

InChI

InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)

Molecular Formula

C20H15ClF3N5

HBD / HBA

2 / 7

可旋转键数

5

重原子数

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A kinase inhibitor used to treat tenosynovial giant cell tumor, a rare and often debilitating condition causing benign but destructive tumors in the joint lining. It works by blocking a signaling pathway that drives the abnormal growth of these tumor cells.

Yes, Pexidartinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3813873. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25151352. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.